ID
26223
Description
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Restless Legs Syndrome
Keywords
Versions (1)
- 10/12/17 10/12/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
October 12, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Visit 3 Week 2 (optional visit)
L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125 Module 1 Visit 3 Week 2 (optional visit)
Description
Concomitant medication
Description
Adverse Experiences
Description
Have there been any adverse experiences observed or elicited by the following direct question to the patient: "Have you felt different in any way since your last visit"? Transcribe any ongoing Baseline Adverse Experiences recorded on page 10, record any changes to ongoing Baseline Adverse Experiences section towards the back of this module.
Data type
text
Description
Study Medication Compliance
Description
Study Medication Compliance
Data type
boolean
Description
Patient continuation